- Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of $0.21 misses by $0.09 .
- Revenue of $97.23M (-6.5% Y/Y) misses by $6.28M .
- Adjusted EBITDA was $56.0 million in the second quarter of 2022, compared to $65.2 million in the second quarter of 2021.
- In 2022, Ironwood continues to expect : U.S. LINZESS Net Sales Growth Low single digits %; total revenue of $420 to $430 million vs. consensus of $429.93M and Adjusted EBITDA of >$250 million.
For further details see:
Ironwood Pharmaceuticals reports Q2 earnings miss; reaffirms FY22 guidance